CERO
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.20 | $0 | -$3M |
| 2025 Q4 | -2.30 | $0 | -$4M |
| 2025 Q3 | -9.10 | $0 | -$3M |
| 2025 Q2 | -61.71 | $0 | -$5M |
| 2025 Q1 | -3.18 | $0 | -$4M |
| 2024 Q4 | 0.56 | $1M | $4M |
| 2024 Q3 | -17.02 | $0 | -$1M |
| 2024 Q2 | -30.23 | $0 | -$4M |